1. Sweden Stocks

  2. •

    Healthcare

  3. •

    Medical - Healthcare Information Services
ContextVision AB (publ)

ContextVision AB (publ)

CONTX.OL
ContextVision AB (publ)NO flagOslo Stock Exchange
3.49
NOK
+0.17
- -
260.04MMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
0.79
0.83
0.93
1.06
1.04
1.17
1.23
1.22
1.27
1.52
1.71
1.69
1.45
1.49
Basic EPS, GAAP
0.06
0.07
0.07
0.05
-0.02
-0.02
0.1
0.16
-0.1
0.37
0.42
0.31
0.01
0.06
Free Cash Flow per Basic Share
0.06
0.02
0.05
0.09
-0.03
-0.03
0.03
0.18
0.06
0.27
0.5
0.38
- -
0.07
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
0.3
- -
- -
- -
Book Value per Share
0.56
0.63
0.69
0.75
0.73
0.71
0.8
0.96
0.46
0.83
0.95
1.17
1.17
- -
Tangible Book Value per Share
0.43
0.44
0.51
0.6
0.63
0.61
0.58
0.72
0.38
0.74
0.92
1.17
1.18
1.18
Basic Weighted Avg Shares
77
77
77
77
77
77
78
77
77
77
77
77
76
76
Sales/Revenue/Turnover
61
64
72
82
81
91
95
95
98
118
132
131
110
113
Operating Margin (%)
10.07
10.68
9.63
7.04
-2.45
0.41
21.06
50.5
45.34
34.91
28.16
15.87
-2.66
2.64
Depreciation Expense
4
4
4
6
5
7
18
10
11
9
9
9
7
7
Net Income, GAAP
5
5
5
4
-2
-1
7
12
-8
29
33
24
1
5
Effective Tax Rate (%)
23.05
22.85
23.23
26.25
- -
- -
24.22
20.65
21.41
18.82
20.68
21.43
25.05
10.22
Profit Margin (%)
7.96
8.42
7.39
5.19
-2.12
-1.3
7.76
12.75
-7.8
24.44
24.76
18.61
0.66
4.17
Working Capital
32
33
40
47
46
44
39
52
20
49
63
80
77
75
LT Debt
- -
- -
- -
- -
- -
- -
5
2
5
2
2
7
9
8
Total Equity
46
51
57
61
59
59
66
80
38
67
78
94
92
91
Return on Invested Capital (%)
10.99
11.07
9.95
7.29
- -
- -
22.75
46.78
51.69
52.98
35.3
16.67
0.3
2.62
Return on Capital (%)
12.06
12.22
10.45
7.61
- -
- -
12.12
16.15
-12.22
51.23
44.54
27.07
1.9
47.73
Return on Common Equity (%)
12.06
11.86
10.45
7.61
-2.99
-2.12
12.58
17.62
-13.94
57.86
47.39
29.57
0.82
- -

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
2
3
3
LT Borrowings
- -
- -
- -
LT Finance Leases
6
9
8
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
76
75
75
Market Capitalization
332
296
256

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
95
101
102
Cash, Cash Equivalents & STI
67
70
69
Accounts Receivable, Net
26
20
31
Inventories
2
1
1
Total Current Liabilities
19
24
27
Payables & Accruals
- -
- -
- -
ST Debt
2
3
3
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
9.58%
11.85%
-2.22%
Free Cash Flow
50.34%
46.72%
-99.31%
Net Income, GAAP
-160.41%
-149.71%
-96.99%
Sales/Revenue/Turnover
4.79%
3.82%
-15.61%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
35
32
30
34
131
2025
26
29
24
32
110
2026
29
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.11
0.05
0.07
0.08
0.31
2025
-0.04
- -
- -
0.05
0.01
2026
0.01
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

APIChat
CEO
Gerald Potzsch
Full Time Employees
35
Sector
Healthcare
Industry
Medical - Healthcare Information Services
Address
HollAendargatan 13, 2 tr Stockholm Sweden 111 36
IPO Date
Jan 3, 2000
Website
contextvision.com
Similar Companies
So-Young International Inc. (SY)
RYAH Group, Inc. (RYAHF)
Volpara Health Technologies Limited (VPAHF)
Tempus AI, Inc. (TEM)
EGF Theramed Health Corp. (TMED.CN)
Data Horizon Corporation (3628.T)
Business
ContextVision AB (publ) is a Sweden-based medical technology software company specializing in image analysis and artificial intelligence for medical imaging systems. The company develops and markets advanced image enhancement software solutions tailored for ultrasound, X-ray, and magnetic resonance imaging (MRI) equipment. Its core products include the Rivent platform with variants such as Rivent for 2D ultrasound image enhancement, Rivent Plus (premium 2D), Rivent 3D for 3D ultrasound, and Rivent Mobile designed for handheld diagnostic devices. ContextVision also offers Altumira/Altumira Plus, an AI-powered image enhancement product for digital radiography, and the Orthopedic Package for orthopedic imaging applications. Additionally, it provides GOPView MRI2Plus, an image enhancement solution for MRI systems. The company delivers customized solutions optimized for each system and application, serving OEMs of medical imaging equipment globally across Asia, Europe, and the Americas. Founded in 1983 and headquartered in Stockholm, Sweden, ContextVision is recognized as a global market leader in medical image enhancement software. The company has recently deepened its strategic clinical development through partnerships with academic institutions and industry leaders, including the University of Washington School of Medicine to advance biomarkers for metabolic dysfunction-associated steatotic liver disease (MASLD), and the University of Waterloo alongside ultrasound expert InPhase Solutions AS to improve ultrasound diagnostics. It also signed a collaboration with AMRA Medical to correlate MRI and ultrasound imaging biomarkers, reflecting expansion in AI-driven medical imaging research. Operationally, ContextVision has executed a share buy-back program initiated in late 2025 to enhance shareholder value. The company continues to invest in future-proofing its software solutions amid market uncertainties, focusing on scalable, AI-based imaging enhancements that improve diagnosis accuracy and speed worldwide. ContextVision’s customer base primarily comprises medical device manufacturers that integrate its software into their ultrasound, X-ray, and MRI systems. Its products span diagnostic fields including radiology, cardiology, women’s health, veterinary medicine, and point-of-care diagnostics. ContextVision maintains a specialized technology and development team dedicated to customizing and optimizing image quality software for diverse medical imaging platforms, reinforcing its position in the healthcare information and technology sector. Overall, ContextVision AB is positioned as a mature medical technology software provider with robust product offerings in image analysis and enhancement, supported by strategic partnerships and ongoing innovation efforts in artificial intelligence applied to medical diagnostics. It operates globally with a focus on OEM medical imaging system providers, headquartered in Stockholm, Sweden, with a founding year of 1983. This description incorporates ContextVision’s comprehensive product portfolio and recent strategic developments, reflecting its status and trajectory in the medical imaging software industry as of late 2025.